Evidence map›Paper›PMID 23786440›Full record

ReviewExpert opinion on medical diagnostics2013

MRI biomarkers for evaluation of treatment efficacy in preclinical diabetic retinopathy.

Bruce A Berkowitz, David Bissig, Oliver Dutczak, Shannon Corbett, Rob North, Robin Roberts

Open access · greenAbstract readReview
In one paragraph

Review in Expert opinion on medical diagnostics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Measuring In Vivo Free Radical Production by the Outer Retina.Investigative ophthalmology & visual science · 2015
    Article
  6. Article
  7. Article
  8. Development of an MRI biomarker sensitive to tetrameric visual arrestin 1 and its reduction via light-evoked translocation in vivo.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2015
    Article
  9. Article
  10. Article
  11. Review
  12. The distribution of Mn2+ in rabbit eyes after topical administration for manganese-enhanced MRI.International journal of clinical and experimental pathology · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Bruce A BerkowitzWayne State University, Department of Anatomy and Cell Biology, Detroit, MI, USA. baberko@med.wayne.edu
David Bissig
Oliver Dutczak
Shannon Corbett
Rob North
Robin Roberts
Wayne State University · US

Funding

Manganese-enhanced MRI Studies of Retinal NeovascularizationR21EY018109 · NEI · WAYNE STATE UNIVERSITY · PI BERKOWITZ, BRUCE A. · 2007 to 2008
$409k
Manganese-Enhanced MRI Studies of Vision Loss with AgingF30AG034752 · NIA · WAYNE STATE UNIVERSITY · PI BISSIG, DAVID PHILIP · 2010 to 2013
$172k
NEI NIH HHS EY018109NEI NIH HHS R21 EY018109NIA NIH HHS AG034752NIA NIH HHS F30 AG034752
6 · The paper itself

Abstract

introductionOne sober consequence of the current epidemic of diabetes mellitus is that an increasing number of people world-wide will partially or completely lose their sight to diabetic retinopathy. Clinically, the sight-threatening complications of diabetes are diagnosed and treated based on visible retinal lesions (e.g., dot-blot hemorrhages or retinal neovascularization). However, such anatomical microvascular lesions are slow to respond with treatment. Thus, there remains an urgent need for imaging biomarkers that are abnormal before retinal lesions are visibly apparent and are responsive to treatment. AREAS COVERED: Here, the development of new MRI methods, such as manganese-enhanced MRI, for evaluating early diabetes-evoked retinal pathophysiology, and its usefulness in guiding new treatments for diabetic retinopathy are reviewed. EXPERT OPINION: In diabetic retinopathy, not all important diagnostic and prognostic needs are well served by optical methods. In the absence of gross anatomy changes, critical times when drug intervention is most likely to be successful at reducing vision loss are missed by most light-based methods and thus provide little help in guiding diagnosis and treatment. For example, before clinical symptoms, is there an optimal time to intervene with drug therapy? Is a drug reaching its target? How does one assess optimal drug dose, schedule, and routes? How well do current experimental models mimic the clinical condition? As discussed herein, MRI is as an analytical tool for addressing these unmet needs. Future clinical applications of MRI can be envisioned such as in clinical trials to assess drug treatment efficacy, or as an adjunct approach to refine or clarify a difficult clinical case. New MRI-generated hypotheses about the pathogenesis of diabetic retinopathy and its treatment are discussed. In the coming years, a substantial growth in the development and application of MRI is expected to address relevant question in both the basic sciences and in the clinic.

Indexed as

AnimalsBiomarkersDiabetic RetinopathyDisease Models, AnimalHumansMagnetic Resonance ImagingBiomarkers

Identifiers

PMID23786440
PMCPMC3912437
OpenAlexW2000981947

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.